Search
Displaying results 1121 to 1130 of 1202.
iCAIR® consortium delivers first results on the way to inhalable drugs against SARS-CoV-2
While the first vaccines against SARS-CoV-2 have now been approved in Europe and other countries, drugs for specific and efficient treatment of COVID-19 have as yet only limited availability – but are urgently needed. Because of the typical long drug development…
New viruses, new challenges
Viruses are small particles - about 1000x smaller than human cells - that exploit their host's metabolism to replicate. There are many thousands of viruses circulating in the animal world that could spread to humans. SARS-CoV-2 has shown how quickly new viruses can…
World Tuberculosis Day 2021: New drugs for old bugs
The department Microbial Natural Products at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), a joint site of Helmholtz Centre for Infection Research (HZI) with Saarland University, is exploring soil bacteria for new active substances to solve these…
Putting pathogens on mute
Pseudomonas aeruginosa is capable of colonizing almost every part of the human body, making it the causative agent of a wide range of infectious diseases. The reason for the success of the bacterium lies, among other things, in its ability to produce and settle in…
Würzburg researchers track down resistance in CAR-T cell therapy
Multiple myeloma is a malignant cancer of the bone marrow. A great hope in the fight against the so far incurable disease rests on new immunotherapies, in particular on the treatment with CAR-T cells. T cells are white blood cells that serve the immune defense. In their…
HZI appoints Fabian Leendertz as founding director of the Helmholtz Institute for One Health
Fabian Leendertz was previously head of the research group “Epidemiology of Highly Pathogenic Microorganisms” at the Robert Koch Institute. As director of the HIOH, Leendertz will first dedicate himself to developing a research concept for the HIOH, which will be…
CoVerage analyses lineage dynamics of SARS-CoV-2 variants
CoVerage enables evaluation of epidemiological dynamics of different SARS-CoV-2 variants This is where the CoVerage web resource comes in. It can be used to identify particularly successful SARS-COV-2 lines and predict their further spread, taking epidemiological…
NoCovid Group in Favor of Considerably More Coronavirus Testing in Germany
If, for example, policymakers want to open up cultural services and the service sector in general, it would be advisable to make the reopening contingent on rapid antigen testing plans, adapted hygiene concepts, and digital data collection. Since this approach would…
‘Big data’ training network for T-cell researchers at the HZI
T cell precursors originate in the bone marrow and mature in the thymus. They then circulate through the bloodstream and secondary lymphoid tissues in search of foreign or altered proteins. Tissue-resident T cells are a subset of T lymphocytes that have left the…
New Chance for Better Pandemic Response
The research team from the TU Braunschweig and the HZI succeeded in generating the antibodies to SARS-CoV-2 in vitro using antibody phage display technology. This was based on the existing HAL9/10 antibody gene library, and for the best-performing antibodies, the…
